More articles about Policy & Legislation

Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.

A Science Policy Forum article argues that a diagnostic method exemption, patent pools and clearinghouses, and a purpose-bound protection regime may provide solutions.

Scientists have proposed a set of recommendations for changing that country's genetic diagnostics law, which they said is "in desperate need of amendment."

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

The IRS and HHS have worked together to provide $1 billion in grants and tax credits to biomedical companies that can lead to new therapeutics and molecular diagnostics.

In a filing with the federal appeals court, the DoJ attempted to strike a balance between rewarding inventions that result from genomic discoveries and ensuring that discoveries of natural phenomena remain in the "storehouse of knowledge of all men." Meanwhile, it's business as usual at the USPTO until the appeals court rules on Myriad's challenged BRCA patents.

Plaintiffs challenging one of Myriad's BRCA patents in the Australian federal court have applied to extend the scope of the case to include additional BRCA patents held by the company.

The DOJ's brief reverses the US government's previous practices regarding gene patents and sides with the District Court's decision that isolated DNA, in and of itself, is not patentable.

According to a notice from SACGHS this week, the committee's charter, slated to expire Sept. 23, will not be renewed by HHS Secretary Kathleen Sebelius.

Although the company is embroiled in a high-profile patent lawsuit involving its flagship BRACAnalysis test, and the FDA's plan to regulate laboratory-developed tests may impact all of its marketed products, Myriad officials maintain a positive outlook.

The Obama plan would expand, simplify, and make permanent the R&D tax credit policy that currently requires renewal.

The European Society of Human Genetics includes among its policy goals oversight for predictive medical genetic tests for utility and validity, marketing, privacy, consent, and counseling.

Many in the genetic testing industry have viewed the Bilski decision as a harbinger of the Supreme Court's thinking for future patent cases, including the anti-gene patenting suit filed against Myriad Genetics.

Myriad Genetics and the University of Utah Research Foundation are appealing a decision rendered in March that found that the company's BRCA gene patents are "unpatentable."

Cancer Voices Australia, the law firm Maurice Blackburn, and breast cancer patient Yvonne D'Arcy this week took legal action in Australia's Federal Court against four biotech companies — Myriad Genetics, Genetic Technologies, Centre de Recherce de Chul in Canada, and the Cancer Institute in Japan — to challenge the legality of gene patents.

According to unofficial results, the Third Frontier extension passed by a 62-38 percent margin, benefiting from a consensus of support among life sciences leaders, business leaders, and government officials from both political parties.

The money is part of the $22 million committed by the state in return for the nonprofit research and technology development institute locating its recently-opened Center for Advanced Drug Research, or CADRE, in Harrisonburg, Va.

The DOE components of the 2010 version of the act would create sequencing facilities and aim to advance synthetic biology.

A US District Court's ruling that Myriad's BRCA patents are invalid will definitely be appealed in the Federal Circuit, and will probably reach the Supreme Court, according to legal experts.

Restrictions in GINA could muddy payors' disease risk prediction models, though it remains to be seen the degree to which the law will "deteriorate" those predictions, Derek van Amerongen, chief medical officer of Humana Health Plans of Ohio, said last week at a conference.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.